Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

Open access

Abstract

AIMS: The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD). METHODS AND RESULTS: Of the theoretical estimated prevalence of 1/500 for heterozygous FH, <1% are diagnosed in most countries. Recently, direct screening in a Northern European general population diagnosed approximately 1/200 with heterozygous FH. All reported studies document failure to achieve recommended LDL cholesterol targets in a large proportion of individuals with FH, and up to 13-fold increased risk of CHD. Based on prevalences between 1/500 and 1/200, between 14 and 34 million individuals worldwide have FH. We recommend that children, adults, and families should be screened for FH if a person or family member presents with FH, a plasma cholesterol level in an adult ≥8 mmol/L(≥310 mg/dL) or a child ≥6 mmol/L(≥230 mg/dL), premature CHD, tendon xanthomas, or sudden premature cardiac death. In FH, low-density lipoprotein cholesterol targets are <3.5 mmol/L(<135 mg/dL) for children, <2.5 mmol/L(<100 mg/dL) for adults, and <1.8 mmol/L(<70 mg/dL) for adults with known CHD or diabetes. In addition to lifestyle and dietary counselling, treatment priorities are (i) in children, statins, ezetimibe, and bile acid binding resins, and (ii) in adults, maximal potent statin dose, ezetimibe, and bile acid binding resins. Lipoprotein apheresis can be offered in homozygotes and in treatment-resistant heterozygotes with CHD. CONCLUSION: Owing to severe underdiagnosis and undertreatment of FH, there is an urgent worldwide need for diagnostic screening together with early and aggressive treatment of this extremely high-risk condition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/eht273

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Estimated per cent of individuals diagnosed with familial hypercholesterolaemia in different countries/territories, as a fraction of those theoretically predicted based on a frequency of 1/500 in the general population. As most countries do not have valid nationwide registries for familial hypercholesterolaemia, several values in this figure represent informed estimates from clinicians/scientists with recognized expertise in and knowledge of familial hypercholesterolaemia in their respective countries. Numbers were provided by Michael Livingston, Steve E. Humphries (UK), Olivier S. Descamps (Belgium).
Figure 1 Estimated per cent of individuals diagnosed with familial hypercholesterolaemia in different countries/territories, as a fraction of those theoretically predicted based on a frequency of 1/500 in the general population. As most countries do not have valid nationwide registries for familial hypercholesterolaemia, several values in this figure represent informed estimates from clinicians/scientists with recognized expertise in and knowledge of familial hypercholesterolaemia in their respective countries. Numbers were provided by Michael Livingston, Steve E. Humphries (UK), Olivier S. Descamps (Belgium).CC BY-NC · PubMed Central
Figure 2 Prevalence of definite or probable familial hypercholesterolaemia according to Dutch Lipid Clinic Network Criteria in the Copenhagen General Population Study by 20-year age groups and by gender. Based on 69 016 individuals. This was originally reported as 1/137 but recalculation suggested that the prevalence of definite or probable familial hypercholesterolaemia combined is closer to 1/200 (personal communication Børge G Nordestgaard). FH, familial hypercholesterolaemia. Adapted from Benn et al.10
Figure 2 Prevalence of definite or probable familial hypercholesterolaemia according to Dutch Lipid Clinic Network Criteria in the Copenhagen General Population Study by 20-year age groups and by gender. Based on 69 016 individuals. This was originally reported as 1/137 but recalculation suggested that the prevalence of definite or probable familial hypercholesterolaemia combined is closer to 1/200 (personal communication Børge G Nordestgaard). FH, familial hypercholesterolaemia. Adapted from Benn et al.10CC BY-NC · PubMed Central
Figure 3 Estimated millions of individuals worldwide with familial hypercholesterolaemia by WHO regions and by income groups. Estimates are shown for the theoretical frequency of heterozygous familial hypercholesterolaemia of 1/500 in the general population,1 as well as for the directly detected frequency of ∼1/200 in the Danish population,10 a typical country in Northern Europe.
Figure 3 Estimated millions of individuals worldwide with familial hypercholesterolaemia by WHO regions and by income groups. Estimates are shown for the theoretical frequency of heterozygous familial hypercholesterolaemia of 1/500 in the general population,1 as well as for the directly detected frequency of ∼1/200 in the Danish population,10 a typical country in Northern Europe.CC BY-NC · PubMed Central
Figure 4 Risk of coronary heart disease as a function of the Dutch Lipid Clinic Network Criteria for a diagnosis of familial hypercholesterolaemia in individuals on or off statin from the general population. Data are based on 69 016 individuals from the Copenhagen General Population Study. CI, confidence interval; FH, familial hypercholesterolaemia; CHD, coronary heart disease = ischaemic heart disease. Adapted from Benn et al.10
Figure 4 Risk of coronary heart disease as a function of the Dutch Lipid Clinic Network Criteria for a diagnosis of familial hypercholesterolaemia in individuals on or off statin from the general population. Data are based on 69 016 individuals from the Copenhagen General Population Study. CI, confidence interval; FH, familial hypercholesterolaemia; CHD, coronary heart disease = ischaemic heart disease. Adapted from Benn et al.10CC BY-NC · PubMed Central
Figure 5 Pathophysiology of heterozygous familial hypercholesterolaemia. LDL, low-density lipoprotein; PCSK9, proprotein convertase subtilisin/kexin type 9.
Figure 5 Pathophysiology of heterozygous familial hypercholesterolaemia. LDL, low-density lipoprotein; PCSK9, proprotein convertase subtilisin/kexin type 9.CC BY-NC · PubMed Central
Figure 6 Overlap of clinical and mutation diagnosis of heterozygous familial hypercholesterolaemia. This figure illustrates the fractions of three different clinical scenarios in a study from Spain,18 and therefore not necessarily the exact proportions for these three groups in other countries. ‘Mutation without clinical diagnosis’ means definite, probable, or possible familial hypercholesterolaemia with a familial hypercholesterolaemia-causing mutation but with less severely elevated LDL cholesterol (i.e. below the diagnostic threshold). LDL, low-density lipoprotein cholesterol; FH, familial hypercholesterolaemia.
Figure 6 Overlap of clinical and mutation diagnosis of heterozygous familial hypercholesterolaemia. This figure illustrates the fractions of three different clinical scenarios in a study from Spain,18 and therefore not necessarily the exact proportions for these three groups in other countries. ‘Mutation without clinical diagnosis’ means definite, probable, or possible familial hypercholesterolaemia with a familial hypercholesterolaemia-causing mutation but with less severely elevated LDL cholesterol (i.e. below the diagnostic threshold). LDL, low-density lipoprotein cholesterol; FH, familial hypercholesterolaemia.CC BY-NC · PubMed Central
Figure 7 Pedigree of a family with familial hypercholesterolaemia. Red and green colours indicate family members with and without heterozygous familial hypercholesterolaemia. CHD, coronary heart disease; LDL, low-density lipoprotein; FH, familial hypercholesterolaemia.
Figure 7 Pedigree of a family with familial hypercholesterolaemia. Red and green colours indicate family members with and without heterozygous familial hypercholesterolaemia. CHD, coronary heart disease; LDL, low-density lipoprotein; FH, familial hypercholesterolaemia.CC BY-NC · PubMed Central
Figure 8 LDL cholesterol burden in individuals with or without familial hypercholesterolaemia as a function of the age of initiation of statin therapy. Data derived from Huijgen et al.20 and Starr et al.21 LDL, low-density lipoprotein; LDL-C, LDL cholesterol; HDL-C, high-density lipoprotein cholesterol; CHD, coronary heart disease; FH, familial hypercholesterolaemia.
Figure 8 LDL cholesterol burden in individuals with or without familial hypercholesterolaemia as a function of the age of initiation of statin therapy. Data derived from Huijgen et al.20 and Starr et al.21 LDL, low-density lipoprotein; LDL-C, LDL cholesterol; HDL-C, high-density lipoprotein cholesterol; CHD, coronary heart disease; FH, familial hypercholesterolaemia.CC BY-NC · PubMed Central
Figure 9 Kaplan–Meier curve estimates of cumulative CHD-free survival among individuals with familial hypercholesterolaemia according to statin treatment (P < 0.001 for difference). Based on 413 and 1537 Dutch subjects with heterozygous familial hypercholesterolaemia on or off statin treatment. CHD, coronary heart disease; FH, familial hypercholesterolaemia. Adapted from Versmissen et al.3
Figure 9 Kaplan–Meier curve estimates of cumulative CHD-free survival among individuals with familial hypercholesterolaemia according to statin treatment (P < 0.001 for difference). Based on 413 and 1537 Dutch subjects with heterozygous familial hypercholesterolaemia on or off statin treatment. CHD, coronary heart disease; FH, familial hypercholesterolaemia. Adapted from Versmissen et al.3CC BY-NC · PubMed Central
Figure 10 Summary of diagnostic and treatment strategies.
Figure 10 Summary of diagnostic and treatment strategies.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 2,761

Metadata

Authors
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., Wiegman, A., Santos, R. D., Watts, G. F., Parhofer, K. G., Hovingh, G. K., Kovanen, P. T., Boileau, C., Averna, M., Boren, J., Bruckert, E., Catapano, A. L., Kuivenhoven, J. A., Pajukanta, P., Ray, K., Stalenhoef, A. F. H., Stroes, E., Taskinen, M.-R., Tybjaerg-Hansen, A., & for the European Atherosclerosis Society Consensus Panel
Affiliations
  • University of Copenhagen (DK)
  • Inserm (FR)
  • University College London (GB)
  • Columbia University (US)
  • Universitat Rovira i Virgili (ES)
  • Hôpital de Jolimont (BE)
  • Sahlgrenska University Hospital (SE)
  • Western University (CA)
  • University of the Witwatersrand (ZA)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Universidade de São Paulo (BR)
  • The University of Western Australia (AU)
  • Ludwig-Maximilians-Universität München (DE)
  • Wihuri Research Institute (FI)
  • University of Palermo (IT)
  • University of Milan (IT)
  • University Medical Center Groningen (NL)
  • University of California, Los Angeles (US)
  • St George's, University of London (GB)
  • Radboud University Medical Center (NL)
Corresponding author
  • Nordestgaard, B. G.
  • Chapman, M. J.
Venue
European Heart Journal
Published
2013-08-15
Volume
34
Issue
45
Pages
3478-3490
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2165624352
Cited by
2,761
References
57
Citations by year
2026: 146 · 2025: 189 · 2024: 197 · 2023: 214 · 2022: 227 · 2021: 246 · 2020: 232 · 2019: 225 · 2018: 277 · 2017: 243 · 2016: 244 · 2015: 178 · 2014: 119 · 2013: 16
FWCI
181.54
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • UWA Profiles and Research Repository (UWA) (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • IRIS UniPA (University of Palermo) (submittedVersion, other-oa)
  • HighWire Press Open Archive (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc)
Funders
  • Amgen
  • AstraZeneca
  • Sanofi
  • F. Hoffmann-La Roche
  • Regeneron Pharmaceuticals
  • Kowa Company
  • British Heart Foundation (RG/08/008/25291)
  • Novo Nordisk Fonden (NNF13OC0004973)
  • National Heart, Lung, and Blood Institute (P01HL028481)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
familial hypercholesterolemia, underdiagnosis, undertreatment, coronary heart disease prevention, LDL cholesterol targets, statins, ezetimibe, bile acid sequestrants, lipoprotein apheresis, tendon xanthomas
MeSH terms
Adult, Anticholesteremic Agents, Child, Child, Preschool, Coronary Disease, Cost-Benefit Analysis, Delivery of Health Care, Female, Forecasting, Heterozygote, Homozygote, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Mutation, Pedigree, Treatment Outcome, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Early Diagnosis, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. https://app.cochat.ai/papers/10.1093/eurheartj/eht273
The paper
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., Wiegman, A., Santos, R. D., Watts, G. F., Parhofer, K. G., Hovingh, G. K., Kovanen, P. T., Boileau, C., Averna, M., Boren, J., . . . for the European Atherosclerosis Society Consensus Panel. (2013). Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal. https://doi.org/10.1093/eurheartj/eht273

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.